Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?

We reported the initial safety results at ASCO in 2022 after the trial was completed in 2021. There are no DLT signal and safety concerns of combining durvalumab with radiotherapy, whether it is conventionally fractionated or hypofractionated. The manuscript is under preparation incorporating some biomarkers done by CIMAC. Efficacy results will also be reported in the future based on the planned analysis after at least 3 years of follow-up. NCI has approved an amendment of the trial to conduct t...